Aortyx
PrivateLast Round
Series A
Jun 12, 2025
Est. Valuation
$21.9M
Total Funding Raised
$25.11M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aortyx operates in Healthcare & Life Sciences and is based in Barcelona. Its latest recorded funding round was a Series A round in June 2025.
Aortyx is a medtech company that develops bioresorbable and biomimetic endovascular patches for the treatment of aortic dissection.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aortyx Comparables
Compare Aortyx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shape Memory Medical | 76% | |
| Cook Group Incorporated | 74% | |
| Terumo Corporation | 74% |
For institutional investors. Book with your work email.
Aortyx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 12, 2025 | ||||
| Grant | Dec 17, 2021 | ||||
| Crowdfunding | Apr 27, 2021 | ||||
| Seed | Mar 11, 2020 | ||||
| Grant | Dec 27, 2019 | ||||
Seed | Nov 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aortyx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Series A, Grant |
| Avançsa | Series A |
| EIT Health | Grant |
| Nara Capital | Series A |
| Clave Capital | Series A |
| Center for Technological Development and Innovation | Series A |
| GENESIS Biomed | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 31, 2026
Open roles increased to 6, 3.2x the trailing average.
- May 17, 2026
Monthly visitors increased 500% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 9, 2026
Aortyx is developing AX-GEN01, a catheter-delivered, bioabsorbable patch that covers aortic tears and promotes natural healing through a minimally invasive approach, with funding supporting its first clinical trial in humans.
- receives_awardNov 9, 2026
Aortyx has received the Catalonia.health 2026 Award and plans to retain its registered headquarters and research and development activities in Catalonia.
For institutional investors. Book with your work email.
Aortyx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aortyx's valuation, stock price, and market status.
Is Aortyx a public or private company?
Aortyx is a private company.
What is the current stock price of Aortyx?
Aortyx is a private company, so its shares have no public market price. Caplight tracks Aortyx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aortyx worth (valuation)?
Aortyx's valuation is estimated at $21.9M based on funding round data.
Can I buy Aortyx stock?
Aortyx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aortyx's last funding round?
Aortyx's most recent funding round was Series A on June 12, 2025.
Who are the main investors in Aortyx?
Key investors in Aortyx include Clave Capital, GENESIS Biomed, Ship2B Ventures, Genesis Ventures.
Will Aortyx IPO soon?
No public IPO plans have been announced for Aortyx.
How can I track Aortyx secondary market activity?
Caplight tracks bids, offers, and trades in Aortyx's shares on secondary markets.